379 Initial safety, efficacy, and product attributes from the SURPASS trial with ADP-A2M4CD8, a SPEAR T-cell therapy incorporating an affinity optimized TCR targeting MAGE-A4 and a CD8α co-receptor

MLA

Gareth Betts, et al. “379 Initial Safety, Efficacy, and Product Attributes from the SURPASS Trial with ADP-A2M4CD8, a SPEAR T-Cell Therapy Incorporating an Affinity Optimized TCR Targeting MAGE-A4 and a CD8α Co-Receptor.” Journal for ImmunoTherapy of Cancer, vol. 8, no. Suppl 3, Nov. 2020. EBSCOhost, https://doi.org/10.1136/jitc-2020-SITC2020.0379.

APA

Gareth Betts, Natalie Bath, Mark Dudley, Tanner Johanns, Ahmed Galal, Samuel Saibil, Adrian Sacher, Spinner William, Alex Tipping, Jessica Tucci, Raymond Luke, Trupti Trivedi, Quan Lin, & Karen Miller. (2020). 379 Initial safety, efficacy, and product attributes from the SURPASS trial with ADP-A2M4CD8, a SPEAR T-cell therapy incorporating an affinity optimized TCR targeting MAGE-A4 and a CD8α co-receptor. Journal for ImmunoTherapy of Cancer, 8(Suppl 3). https://doi.org/10.1136/jitc-2020-SITC2020.0379

Chicago

Gareth Betts, Natalie Bath, Mark Dudley, Tanner Johanns, Ahmed Galal, Samuel Saibil, Adrian Sacher, et al. 2020. “379 Initial Safety, Efficacy, and Product Attributes from the SURPASS Trial with ADP-A2M4CD8, a SPEAR T-Cell Therapy Incorporating an Affinity Optimized TCR Targeting MAGE-A4 and a CD8α Co-Receptor.” Journal for ImmunoTherapy of Cancer 8 (Suppl 3). doi:10.1136/jitc-2020-SITC2020.0379.